iverpool Experimental Cancer Medicine Centre biomarker discovery programme

Not Applicable

• Conditions: Pancreas, head and neck, breast, hepatobiliary and lung cancers; Cancer

• Registration Number: ISRCTN74588872
• Lead Sponsor: niversity of Liverpool

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-12-10
• Last Update Posted: 20 November 2023
• Study Completion: 2028-03-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

This will vary according to tumour type. In general, the populations will consist of patients undergoing standard diagnosis and treatment for malignancies and premalignant disease in disease areas which are of interest to the LECMC. All patients must, in addition to fulfilling the medical requirements, complete an informed consent procedure including the physical signing of a consent form.

Head and Neck:
Presumptive or acute diagnosis of head and neck squamous cell cancer (HNSCC) or recognised oral premalignant conditions (OPML) including but not exhaustively oral epithelial dysplasia (OED), proliferative verrucous leucoplakia (PVL), and those individuals who have been treated for these conditions in the past.

Pancreas:
All patients with suspected or actual diagnosed Pancreatic Ductal Adenocarcinoma (PDAC), and those individuals who are undergoing or have been treated for PDAC in the past.

Breast:
Samples from all patients with histologically and/or cytologically confirmed early, locally advanced or metastatic breast cancer including patients with central nervous system (CNS) involvement defined as metastases to the brain parenchyma, metastases to the leptomeninges and/or paraneoplastic disorders.

Added 09/11/2023:
Hepatobiliary:
All patients with suspected or actual diagnosis of primary or secondary hepatobiliary malignancy.

Thoracic:
Presumptive, past or actual diagnosis of lung cancer, thymic malignancy or mesothelioma, and those individuals who have been treated for these conditions in the past.

Exclusion Criteria

1. Individuals who are unable to consent
2. Under 18 years of age
3. Unable to read or translate patient information sheet and/or consent form

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure for this programme will be the number of publications produced by research projects supported by the programme. Each project supported by the programme will have its own outcome measures which will be considered by the programme management team during the project adoption process.

Secondary Outcome Measures

Name	Time	Method
There are no secondary outcome measures